Trump CMS faces bipartisan pushback over Medicare proposal tied

The first thing that jumps out about this bipartisan backlash is that it’s bipartisan. When Bernie Sanders and Tom Cotton land on the same side against a Medicare policy, the administration should probably slow down. The proposal in question would tie what Medicare pays for newer cancer drugs to prices in other countries. It sounds clever. It could even save money. But it assumes a new therapy is no different than a bag of cement, and that’s a dangerous way to treat American patients.

Cancer doesn’t wait for a pricing experiment. If a targeted treatment or an immunotherapy gets squeezed in this model, the immediate victim isn’t a spreadsheet — it’s a mother or a grandfather whose next scan is next week. The drug companies know this too, and they’ll respond predictably by spending less on the next generation of oncology research. We’re not crying for pharma executives. But the real cost-cutters in this system are innovation and risk-taking, and this policy would tax both.

The conservative case for lowering drug prices is about breaking up dishonest middlemen, not capping hope. President Trump was right to pound the table on drug costs. Yet this proposal heads in the wrong direction by punishing newness instead of rewarding it. Lawmakers who question this aren’t defending the old system; they’re pointing out that a cure that never gets developed has no price at all. Listen to them. The administration can find savings without making cancer patients shoulder the burden as collateral damage.